Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HBM Holdings Ltd. ( (HK:2142) ) just unveiled an announcement.
HBM Holdings Ltd. announced significant progress in its share repurchase program, having repurchased HK$130 million worth of shares in 2025, reflecting its commitment to enhancing shareholder value. The company has also entered into multiple strategic collaborations, including a major partnership with AstraZeneca, which could yield up to US$4.4 billion in milestone payments, underscoring its strong market positioning and potential for growth.
More about HBM Holdings Ltd.
HBM Holdings Ltd. operates in the biotechnology industry, focusing on developing innovative therapies and collaborating with global partners to advance treatments in immunology, oncology, and other areas. The company is known for its strategic partnerships and technology platforms that have broad application prospects.
Average Trading Volume: 11,404,712
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.67B
For an in-depth examination of 2142 stock, go to TipRanks’ Overview page.